단백질체학 : 시장 점유율 분석, 산업 동향, 통계, 성장 예측(2025-2030년)

The proteomics market size is estimated at USD 29.92 billion in 2025 and is projected to advance to USD 52.83 billion by 2030, reflecting a 12.04% CAGR.

Expansion is propelled by rapid adoption of high-throughput mass-spectrometry systems, AI-enabled single-cell workflows, and growing integration of proteomic readouts into precision-medicine programs. Pharmaceutical firms are embedding proteomics across target discovery, lead optimization, and biomarker validation, while contract research organizations (CROs) scale specialized services. Regionally, continued R&D funding and entrenched biopharma infrastructure anchor North American leadership, whereas vigorous investment across China, India, Japan, and South Korea positions Asia-Pacific as the fastest-growing arena. Competitive dynamics centre on platform consolidation: large vendors acquire niche innovators to deliver end-to-end reagent, instrument, and analytics solutions that shorten project timelines for drug-development customers.

Global Proteomics Market Trends and Insights

Rising Demand for Personalized & Precision Medicine

Growing clinical evidence links protein-based biomarkers with disease stratification, fostering routine inclusion of proteomic panels in large cohort studies. Thermo Fisher Scientific's Olink platform's selection for the UK Biobank's programme to profile 5,400 proteins across 600,000 samples exemplifies this shift, creating multidimensional datasets that guide therapeutic selection. Proteomic fitness scores now complement genetic risk metrics and have demonstrated responsiveness to lifestyle interventions, underscoring value for preventive-care planning. Organ-specific ageing clocks derived from circulating protein signatures are informing early intervention strategies. Pharma stakeholders view these insights as pivotal for companion-diagnostic development, reinforcing sustained demand for next-generation assay platforms.

Increasing R&D Expenditure and Public Funding

Consortia funding models that pool biopharma and public financing are scaling infrastructure once limited to elite academic centres. The UK Biobank's proteomics initiative, funded by 14 biopharmaceutical companies, represents a paradigm shift where industry collaboration drives large-scale proteomic studies that were previously unfeasible. Government grants across China, Japan, and Korea subsidize high-resolution mass-spectrometry installations and cloud-based data hubs, lowering barriers for start-up laboratories. Venture capital flows toward AI-native proteomic software firms, accelerating automated pattern-recognition tools that cut analysis times from days to minutes and broaden user access.

High Capital & Operating Cost of Instruments

Top-tier Orbitrap or trapped-ion-mobility platforms routinely exceed USD 1 million per system, and annual service contracts may add 10% of purchase price. Labs must also budget for consumables, vacuum infrastructure, and environmental controls. Although university-level initiatives such as the E3 method reduce sample-prep costs, hardware outlays remain a hurdle for mid-tier institutions. Shared-facility models and CRO outsourcing mitigate entry costs yet can constrain experimental flexibility.

Other drivers and restraints analyzed in the detailed report include:

1. Rapid Advances in High-Throughput MS & LC-MS Platforms
2. Growing Adoption in Drug-Discovery Pipelines
3. Shortage of Skilled Bioinformaticians & Proteomics Experts

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Reagents accounted for 69.78% of the proteomics market share in 2024, reflecting their consumable nature and indispensability across sample lysis, enrichment, labelling, and quantitation steps. High adoption of bioorthogonal tags that improve detection specificity sustains robust reorder volumes. The instruments sub-segment benefits from premium pricing on ultrahigh-resolution spectrometers designed for single-cell assays. Software and services are growing at a 13.56% CAGR as laboratories confront rising data volumes and seek AI-driven analytics platforms that remove bioinformatics bottlenecks. Cloud-native pipelines that integrate quality-control dashboards with automated annotation broaden accessibility for non-specialists, supporting overall proteomics market expansion.

Second paragraph: Adoption of subscription licensing accelerates vendor revenue, while managed-service contracts bundle instrument monitoring, data storage, and compliance reporting into predictable fees. CROs leverage modular software to offer rapid-turnaround studies, allowing smaller biotech companies to conduct discovery without installing costly hardware. As multi-omics integration becomes routine, hybrid workflows that co-analyze transcriptomic and proteomic layers rely on middleware capable of harmonizing heterogeneous datasets, further fueling demand for specialized analytics solutions within the proteomics market.

Mass-spectrometry platforms captured 30.69% of the proteomics market share in 2024, owing to continuous innovation in ion-optics and detector design that extends resolving power past 200,000 for proteins up to 80 kDa. Time-of-flight-Orbitrap hybrids deliver sub-ppm mass accuracy at scan speeds supporting population-scale cohort studies. The proteomics market size tied to next-generation sequencing is forecast to expand at 13.71% CAGR, reflecting the converging utility of DNA-encoded libraries and ribosome-display systems in mapping protein-interaction networks. Sequencing-based readouts provide orthogonal validation of post-translational modifications and support high-multiplex quantitation.

Second paragraph: Complementary methods such as microfluidic-based separation and spatially resolved protein arrays gain traction for tissue-context analysis. Integration of chromatography upgrades, including ultra-high-pressure variants, enhances front-end separation and reduces sample carry-over, boosting confidence in low-abundance peptide identification. Vendors now package cross-platform kits that streamline transfer between LC-MS, capillary electrophoresis, and imaging-based workflows, ensuring method continuity for longitudinal studies within the proteomics market.

The Proteomics Market Report is Segmented by Component (Instruments and More), Technology (Mass Spectrometry and More), Application (Drug Discovery & Development and More), End-User (Pharmaceutical & Biotechnology Companies and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America retained 44.31% of global revenue in 2024 due to an entrenched biopharma enterprise, sustained National Institutes of Health funding, and large-scale precision-medicine cohorts. The United States hosts leading vendors such as Thermo Fisher Scientific, which has closed 54 strategic acquisitions, averaging USD 3.09 billion, to deepen technology breadth. Canada expands through public-private genomics initiatives, while Mexico builds niche CRO capabilities serving regional generics manufacturers.

Europe recorded 11.96% CAGR with Germany, the United Kingdom, and France as principal contributors. The UK Biobank's proteome programme exemplifies pan-European collaboration and underpins an ecosystem of contract-analysis providers that interpret multi-omic datasets for pharma sponsors. Germany leverages domestic precision-instrument engineering to export high-performance LC-MS systems, whereas France and Italy scale clinical trial networks that integrate proteomics endpoints, strengthening the proteomics market across the continent.

Asia-Pacific is positioned as the fastest-growing region at 13.84% CAGR through 2030. China's Five-Year Plan earmarks biotechnology as a strategic pillar, and patent grants for novel diagnostic panels validate domestic innovation capacity. India draws investment into cost-effective CRO hubs and establishes joint-degree programmes in proteogenomics to alleviate talent shortages. Japan pioneers robotics-enabled sample preparation, while South Korea subsidizes AI-native bio-informatics start-ups. Australia's translational research alliances focus on agrigenomics and rare-disease diagnostics, broadening the addressable proteomics market. Middle East and Africa show progressive adoption in tertiary hospitals, and Brazil leads South American uptake through vaccine-related proteome studies.

1. Agilent Technologies
2. Alamar Biosciences, Inc.
3. Bioneer
4. Bioinformatics Solutions Inc.
5. Bio-Rad Laboratories
6. Bruker
7. Creative Proteomics
8. Danaher
9. Evosep
10. GE Healthcare
11. Illumina
12. Merck
13. Nautilus Biotechnology
14. Olink Holding AB
15. Oxford Nanopore Technologies
16. Promega
17. Proteome Factory AG
18. Proteome Sciences PLC
19. QIAGEN
20. Revvity, Inc.
21. Seer
22. Shimadzu
23. SomaLogic
24. Thermo Fisher Scientific
25. Waters Corporation

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising demand for personalized & precision medicine
  • 4.2.2 Increasing R&D expenditure and public funding
  • 4.2.3 Rapid advances in high-throughput MS & LC-MS platforms
  • 4.2.4 Growing adoption of proteomics in drug discovery pipelines
  • 4.2.5 AI-enabled single-cell proteomics breakthroughs
  • 4.2.6 Expanding use of proteomics in agri-genomics & food safety
• 4.3 Market Restraints
  • 4.3.1 High capital & operating cost of instruments
  • 4.3.2 Shortage of skilled bioinformaticians & proteomics experts
  • 4.3.3 Data-analysis complexity & lack of workflow standards
  • 4.3.4 Limited throughput for native membrane-protein studies
• 4.4 Supply Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Component
  • 5.1.1 Instruments
  • 5.1.2 Reagents
  • 5.1.3 Software and Services
• 5.2 By Technology
  • 5.2.1 Mass Spectrometry
  • 5.2.2 Spectroscopy
  • 5.2.3 Chromatography
  • 5.2.4 Next-Generation Sequencing
  • 5.2.5 Protein Microarrays
  • 5.2.6 Microfluidics
  • 5.2.7 X-ray Crystallography
  • 5.2.8 Other Technologies
• 5.3 By Application
  • 5.3.1 Drug Discovery & Development
  • 5.3.2 Clinical Diagnostics
  • 5.3.3 Biomarker Discovery
  • 5.3.4 Precision and Personalized Medicine
  • 5.3.5 Agricultural & Environmental Proteomics
  • 5.3.6 Other Applications
• 5.4 By End-User
  • 5.4.1 Pharmaceutical & Biotechnology Companies
  • 5.4.2 Academic & Research Institutes
  • 5.4.3 Contract Research Organizations
  • 5.4.4 Other End-Users
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Competitive Benchmarking
• 6.3 Market Share Analysis
• 6.4 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.4.1 Agilent Technologies Inc.
  • 6.4.2 Alamar Biosciences, Inc.
  • 6.4.3 Bioneer Corporation
  • 6.4.4 Bioinformatics Solutions Inc.
  • 6.4.5 Bio-Rad Laboratories Inc.
  • 6.4.6 Bruker Corporation
  • 6.4.7 Creative Proteomics
  • 6.4.8 Danaher Corporation
  • 6.4.9 Evosep
  • 6.4.10 GE Healthcare
  • 6.4.11 Illumina Inc.
  • 6.4.12 Merck KGaA
  • 6.4.13 Nautilus Biotechnology
  • 6.4.14 Olink Holding AB
  • 6.4.15 Oxford Nanopore Technologies
  • 6.4.16 Promega Corporation
  • 6.4.17 Proteome Factory AG
  • 6.4.18 Proteome Sciences PLC
  • 6.4.19 QIAGEN N.V.
  • 6.4.20 Revvity, Inc.
  • 6.4.21 Seer Inc.
  • 6.4.22 Shimadzu Corporation
  • 6.4.23 SomaLogic Inc.
  • 6.4.24 Thermo Fisher Scientific Inc.
  • 6.4.25 Waters Corporation

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment